Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 355

1.

Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial.

Lannfelt L, Blennow K, Zetterberg H, Batsman S, Ames D, Harrison J, Masters CL, Targum S, Bush AI, Murdoch R, Wilson J, Ritchie CW; PBT2-201-EURO study group..

Lancet Neurol. 2008 Sep;7(9):779-86. doi: 10.1016/S1474-4422(08)70167-4. Erratum in: Lancet Neurol. 2009 Nov;8(11):981.

PMID:
18672400
2.

Metal protein attenuating compounds for the treatment of Alzheimer's dementia.

Sampson EL, Jenagaratnam L, McShane R.

Cochrane Database Syst Rev. 2014 Feb 21;(2):CD005380. doi: 10.1002/14651858.CD005380.pub5. Review.

PMID:
24563468
3.

Metal protein attenuating compounds for the treatment of Alzheimer's dementia.

Sampson EL, Jenagaratnam L, McShane R.

Cochrane Database Syst Rev. 2012 May 16;(5):CD005380. doi: 10.1002/14651858.CD005380.pub4. Review. Update in: Cochrane Database Syst Rev. 2014;(2):CD005380.

4.

Safety, tolerability, and efficacy of PBT2 in Huntington's disease: a phase 2, randomised, double-blind, placebo-controlled trial.

Huntington Study Group Reach2HD Investigators..

Lancet Neurol. 2015 Jan;14(1):39-47. doi: 10.1016/S1474-4422(14)70262-5.

PMID:
25467848
5.

Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial.

Wilcock GK, Black SE, Hendrix SB, Zavitz KH, Swabb EA, Laughlin MA; Tarenflurbil Phase II Study investigators..

Lancet Neurol. 2008 Jun;7(6):483-93. doi: 10.1016/S1474-4422(08)70090-5. Erratum in: Lancet Neurol. 2011 Apr;10(4):297. Lancet Neurol. 2008 Jul;7(7):575.

PMID:
18450517
6.

PBT2 rapidly improves cognition in Alzheimer's Disease: additional phase II analyses.

Faux NG, Ritchie CW, Gunn A, Rembach A, Tsatsanis A, Bedo J, Harrison J, Lannfelt L, Blennow K, Zetterberg H, Ingelsson M, Masters CL, Tanzi RE, Cummings JL, Herd CM, Bush AI.

J Alzheimers Dis. 2010;20(2):509-16. doi: 10.3233/JAD-2010-1390.

PMID:
20164561
7.

Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study.

Winblad B, Andreasen N, Minthon L, Floesser A, Imbert G, Dumortier T, Maguire RP, Blennow K, Lundmark J, Staufenbiel M, Orgogozo JM, Graf A.

Lancet Neurol. 2012 Jul;11(7):597-604. doi: 10.1016/S1474-4422(12)70140-0.

PMID:
22677258
8.

Galantamine for Alzheimer's disease.

Olin J, Schneider L.

Cochrane Database Syst Rev. 2001;(4):CD001747. Review. Update in: Cochrane Database Syst Rev. 2002;(3):CD001747.

PMID:
11687119
9.

Galantamine for Alzheimer's disease.

Olin J, Schneider L.

Cochrane Database Syst Rev. 2002;(3):CD001747. Review. Update in: Cochrane Database Syst Rev. 2004;(4):CD001747.

PMID:
12137632
10.

Optimal dosing of galantamine in patients with mild or moderate Alzheimer's disease: post Hoc analysis of a randomized, double-blind, placebo-controlled trial.

Aronson S, Van Baelen B, Kavanagh S, Schwalen S.

Drugs Aging. 2009;26(3):231-9. doi: 10.2165/00002512-200926030-00004.

PMID:
19358618
11.

A Phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease.

Aisen PS, Saumier D, Briand R, Laurin J, Gervais F, Tremblay P, Garceau D.

Neurology. 2006 Nov 28;67(10):1757-63.

PMID:
17082468
12.
13.

Donepezil in patients with subcortical vascular cognitive impairment: a randomised double-blind trial in CADASIL.

Dichgans M, Markus HS, Salloway S, Verkkoniemi A, Moline M, Wang Q, Posner H, Chabriat HS.

Lancet Neurol. 2008 Apr;7(4):310-8. doi: 10.1016/S1474-4422(08)70046-2.

PMID:
18296124
14.

Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial.

Farlow M, Potkin S, Koumaras B, Veach J, Mirski D.

Arch Neurol. 2003 Jun;60(6):843-8.

PMID:
12810489
15.

Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial.

Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, Eisner L, Kirby L, Rovira MB, Forette F, Orgogozo JM; AN1792(QS-21)-201 Study Team..

Neurology. 2005 May 10;64(9):1553-62.

PMID:
15883316
16.

Safety and tolerability of donepezil at doses up to 20 mg/day: results from a pilot study in patients with Alzheimer's disease.

Doody RS, Corey-Bloom J, Zhang R, Li H, Ieni J, Schindler R.

Drugs Aging. 2008;25(2):163-74.

PMID:
18257603
17.

Effect of copper intake on CSF parameters in patients with mild Alzheimer's disease: a pilot phase 2 clinical trial.

Kessler H, Pajonk FG, Bach D, Schneider-Axmann T, Falkai P, Herrmann W, Multhaup G, Wiltfang J, Schäfer S, Wirths O, Bayer TA.

J Neural Transm (Vienna). 2008 Dec;115(12):1651-9. doi: 10.1007/s00702-008-0136-2.

PMID:
18972062
18.

Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer's disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial.

Wilkinson D, Windfeld K, Colding-Jørgensen E.

Lancet Neurol. 2014 Nov;13(11):1092-9. doi: 10.1016/S1474-4422(14)70198-X.

PMID:
25297016
20.

A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.

Tariot PN, Cummings JL, Katz IR, Mintzer J, Perdomo CA, Schwam EM, Whalen E.

J Am Geriatr Soc. 2001 Dec;49(12):1590-9.

PMID:
11843990
Items per page

Supplemental Content

Support Center